drugset / Trial / NCT05767047
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
NaParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2036-03-17
- Completion
- 2036-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 10 mg | Oral |
| Subject | Apremilast | Small molecule | 20 mg | Oral |
| Subject | Apremilast | Small molecule | 30 mg | Oral |